Interactive Evidence Tool
Compare Peptides Side by Side
Select two or three peptides or related compounds to compare their mechanisms, receptor targets, regulatory status, direct human evidence, safety context, WADA status, and primary sources.
Shareable comparison pages
Popular peptide & metabolic comparisons
39 clean comparison pages indexed
Open a clean, shareable comparison URL built from the same evidence dataset as the interactive tool below. The most useful starting points are shown here; additional comparisons surface through search and related-comparison links.
CagriSema vs Tirzepatide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
CagriSema vs Retatrutide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Zenagamtide (Amycretin) vs Retatrutide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
CagriSema vs Zenagamtide (Amycretin)
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Survodutide vs Retatrutide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Mazdutide vs Retatrutide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Cagrilintide vs Retatrutide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
MariTide vs Retatrutide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Semaglutide vs Tirzepatide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Tirzepatide vs Retatrutide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Semaglutide vs Retatrutide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Semaglutide vs Tirzepatide vs Retatrutide
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
CJC-1295 vs Ipamorelin
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Tesamorelin vs CJC-1295
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
BPC-157 vs TB-500
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
BPC-157 vs GHK-Cu
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
MT1 / Melanotan I / Afamelanotide vs MT2 / Melanotan II
Compare mechanism, regulatory status, human evidence, safety context, and primary sources.
Open comparison →
Save this comparison
Keep the current two- or three-compound comparison for quick access in My Tools.
Loading comparison tool...
How BACToBasics grades evidence
5 levelsOpen the evidence scale when you need a reminder of what each label means.
How BACToBasics grades evidence
5 levelsOpen the evidence scale when you need a reminder of what each label means.
Regulatory-grade / large Phase 3
FDA-approved products or compounds supported by large late-stage development programs and substantial direct human clinical evidence.
Phase 3 investigational
Late-stage human development exists, but the compound remains investigational and does not yet have an FDA-approved product.
Human pharmacology / early clinical
Direct human exposure or controlled early studies exist, but they do not establish the broad therapeutic or performance claims commonly made online.
Very limited human evidence
Only small, exploratory, uncontrolled, route-limited, or otherwise insufficient human evidence is available.
No meaningful direct human therapeutic evidence
Claims rely mainly on animal, cell, mechanistic, endogenous-biology, or related-molecule evidence rather than direct human therapeutic studies of the exact compound.
Why exact compound identity matters
Similar names do not guarantee similar evidence. CJC-1295 is a good example: the original human literature studied the long-acting DAC compound, while products marketed as “CJC-1295 No DAC” are generally discussed as Mod GRF 1-29 and should not inherit the DAC evidence base.
The same principle applies to TB-500 versus full-length thymosin beta-4, GHK-Cu topical versus injectable use, and naturally occurring MOTS-C biology versus administered MOTS-C as a research product.
Peptide Comparison FAQ
Tap a question to expand the answer without filling the page with text you may not need.
What does the human evidence level mean?
BACToBasics separates regulatory-grade and Phase 3 evidence from early human pharmacology, very limited exploratory human evidence, and compounds without meaningful direct human therapeutic evidence. The label describes the evidence base, not whether a compound is appropriate for a person to use.
Does FDA-approved mean a compound is approved for every use discussed online?
No. Approval is product- and indication-specific. For example, tesamorelin has an FDA-approved product for a specific HIV-associated lipodystrophy indication, but that does not make it an approved general weight-loss or bodybuilding treatment.
Why does the tool separate human biology from human intervention evidence?
A substance can be measured or studied naturally in humans without there being evidence that administering it as a drug is safe or effective. MOTS-C is a clear example of why those evidence types should not be treated as the same thing.
Is the WADA column anti-doping advice?
No. It is an educational summary of the 2026 prohibited-list context. Anti-doping rules and classifications can change, and athletes should verify current rules directly with the applicable anti-doping authority.
BACToBasics provides educational information only. This comparison tool is not medical advice, dosing advice, treatment guidance, anti-doping advice, or a recommendation to use any peptide or medication.